Price History
Feb 9, 2026 — Mar 27, 2026Investment Snapshot
- P/B of 0.16 — trading below book value
- Piotroski F-Score 3/9 — signs of financial weakness
- Loss-making — negative ROE of -73.8%
PMGC Holdings Inc. - Common Stock (ELAB) is a Healthcare company operating in Pharmaceutical Preparations, listed on the NASDAQ , with a market capitalisation of $1 million . Key value metrics: P/B ratio 0.16, Piotroski F-Score 3 out of 9 .
Value Score
Key Metrics
Current vs 5-Year Average
Based on 3 years of SEC filingsRevenue & Net Income
Financial Statements
| Metric | FY22 | FY23 | FY24 |
|---|---|---|---|
| Revenue | $X.XB | $X.XB | $X.XB |
| Gross Profit | $X.XB | $X.XB | $X.XB |
| Operating Income | $X.XB | $X.XB | $X.XB |
| Net Income | $X.XB | $X.XB | $X.XB |
| EBITDA | $X.XB | $X.XB | $X.XB |
| Total Assets | $X.XB | $X.XB | $X.XB |
| Total Liabilities | $X.XB | $X.XB | $X.XB |
PMGC Holdings Inc. - Common Stock — Fundamental Analysis Summary
On financial health, ELAB shows a weak Piotroski F-Score of 3/9, a signal of deteriorating financial health, and negative return on equity of -73.8% (sector average: -19.8%), and manageable leverage with a debt-to-equity ratio of 0.76.
StockPik's composite Value Score for ELAB is 63/100 — an above-average value rating. The score is built from ten fundamental signals: P/E, P/B, PEG ratio, P/S ratio, return on equity, gross margin, debt-to-equity, current ratio, dividend yield, and Piotroski F-Score.
ELAB reports a high gross margin of 66.7% (sector average: 33.5%) and a negative operating margin of -305.4%.
ELAB shows earnings declining at 45%.